(Q44429750)

2 December 2017

title

Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies (English)

1 reference

2 December 2017

1 reference

J. Y. Reginster

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12730797

30 December 2023

P. J. Meunier

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12730797

30 December 2023

language of work or name

English

0 references

publication date

12 March 2003

1 reference

full work available at URL

2 December 2017

http://link.springer.com/content/pdf/10.1007/s00198-002-1349-0.pdf

file format

Portable Document Format

1 reference

DOI

https://api.crossref.org/works/10.1007/S00198-002-1349-0

http://link.springer.com/article/10.1007/s00198-002-1349-0/fulltext.html

30 December 2023

1 reference

https://api.crossref.org/works/10.1007/S00198-002-1349-0

http://link.springer.com/content/pdf/10.1007/s00198-002-1349-0

30 December 2023

1 reference

DOI

https://api.crossref.org/works/10.1007/S00198-002-1349-0

Osteoporosis International

30 December 2023

published in

1 reference

2 December 2017

volume

14 Suppl 3

1 reference

2 December 2017

page(s)

S56-65

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-002-1349-0

2 December 2017

exact match

0 references

cites work

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

The use of different dual X-ray absorptiometry brands in a multicenter clinical trial: consequences and limits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

Prevention of postmenopausal bone loss by tiludronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

Treatment of postmenopausal osteoporosis with transdermal estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-002-1349-0

Treatment of postmenopausal osteoporosis

21 January 2018

1 reference

12 December 2020

Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)

1 reference

12 December 2020

Prevention of early postmenopausal bone loss with cyclical etidronate

1 reference

12 December 2020

Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration

1 reference

12 December 2020

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

12 December 2020

Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial

1 reference

12 December 2020

Identifiers

DOI

0 references

1 reference